Literature DB >> 10085043

Vaccination and protection of pigs against pleuropneumonia with a vaccine strain of Actinobacillus pleuropneumoniae produced by site-specific mutagenesis of the ApxII operon.

C T Prideaux1, C Lenghaus, J Krywult, A L Hodgson.   

Abstract

The production of toxin (Apx)-neutralizing antibodies during infection plays a major role in the induction of protective immunity to Actinobacillus pleuropneumoniae reinfection. In the present study, the gene encoding the ApxII-activating protein, apxIIC, was insertionally inactivated on the chromosome of a serovar 7 strain, HS93. Expression of the structural toxin, ApxIIA, and of the two genes required for its secretion, apxIB and apxID, still occurs in this strain. The resulting mutant strain, HS93C- Ampr, was found to secrete the unactivated toxin. Pigs vaccinated with live HS93C- Ampr via the intranasal route were protected against a cross-serovar challenge with a virulent serovar 1 strain of A. pleuropneumoniae. This is the first reported vaccine strain of A. pleuropneumoniae which can be delivered live to pigs and offers cross-serovar protection against porcine pleuropneumonia.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10085043      PMCID: PMC96553          DOI: 10.1128/IAI.67.4.1962-1966.1999

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  33 in total

1.  Seroepidemiology of Actinobacillus pleuropneumoniae.

Authors:  R Nielsen
Journal:  Can Vet J       Date:  1988-07       Impact factor: 1.008

2.  Isolation and molecular characterization of spontaneously occurring cytolysin-negative mutants of Actinobacillus pleuropneumoniae serotype 7.

Authors:  C Anderson; A A Potter; G F Gerlach
Journal:  Infect Immun       Date:  1991-11       Impact factor: 3.441

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Antibody- and cell-mediated immune responses of Actinobacillus pleuropneumoniae-infected and bacterin-vaccinated pigs.

Authors:  S E Furesz; B A Mallard; J T Bossé; S Rosendal; B N Wilkie; J I MacInnes
Journal:  Infect Immun       Date:  1997-02       Impact factor: 3.441

5.  Identification of a second hemolysin (HlyII) in Actinobacillus pleuropneumoniae serotype 1 and expression of the gene in Escherichia coli.

Authors:  J Frey; H van den Bosch; R Segers; J Nicolet
Journal:  Infect Immun       Date:  1992-04       Impact factor: 3.441

6.  Grouping of Actinobacillus pleuropneumoniae strains of serotypes 1 through 12 on the basis of their virulence in mice.

Authors:  J P Komal; K R Mittal
Journal:  Vet Microbiol       Date:  1990-11       Impact factor: 3.293

7.  Characterization of a non-hemolytic mutant of Actinobacillus pleuropneumoniae serotype 5: role of the 110 kilodalton hemolysin in virulence and immunoprotection.

Authors:  T J Inzana; J Todd; J N Ma; H Veit
Journal:  Microb Pathog       Date:  1991-04       Impact factor: 3.738

8.  Protection of mice against challenge with homologous and heterologous serovars of Actinobacillus pleuropneumoniae after live vaccination.

Authors:  C T Prideaux; L Pierce; J Krywult; A L Hodgson
Journal:  Curr Microbiol       Date:  1998-11       Impact factor: 2.188

9.  Distribution of Pasteurella haemolytica and Pasteurella multocida in the bovine lung following vaccination and challenge exposure as an indicator of lung resistance.

Authors:  P R Newman; R E Corstvet; R J Panciera
Journal:  Am J Vet Res       Date:  1982-03       Impact factor: 1.156

10.  Evaluation of a Killed Vaccine Against Porcine Pleuropneumonia Due to Haemophilus pleuropneumoniae.

Authors:  R Higgins; S Larivière; K R Mittal; G P Martineau; P Rousseau; J Cameron
Journal:  Can Vet J       Date:  1985-02       Impact factor: 1.008

View more
  10 in total

1.  Use of an Actinobacillus pleuropneumoniae multiple mutant as a vaccine that allows differentiation of vaccinated and infected animals.

Authors:  Alexander Maas; Ilse D Jacobsen; Jochen Meens; Gerald-F Gerlach
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

2.  Influences of ORF1 on the virulence and immunogenicity of Actinobacillus pleuropneumoniae.

Authors:  Fangyan Yuan; Jinlin Liu; Yi Guo; Chen Tan; Shulin Fu; Jin Zhao; Huanchun Chen; Weicheng Bei
Journal:  Curr Microbiol       Date:  2011-10-01       Impact factor: 2.188

3.  Actinobacillus pleuropneumoniae iron transport and urease activity: effects on bacterial virulence and host immune response.

Authors:  N Baltes; W Tonpitak; G F Gerlach; I Hennig-Pauka; A Hoffmann-Moujahid; M Ganter; H J Rothkötter
Journal:  Infect Immun       Date:  2001-01       Impact factor: 3.441

4.  Functional pentameric formation via coexpression of the Escherichia coli heat-labile enterotoxin B subunit and its fusion protein subunit with a neutralizing epitope of ApxIIA exotoxin improves the mucosal immunogenicity and protection against challenge by Actinobacillus pleuropneumoniae.

Authors:  Jung-Mi Kim; Seung-Moon Park; Jung-Ae Kim; Jin-Ah Park; Min-Hee Yi; Nan-Sun Kim; Jong-Lye Bae; Sung Goo Park; Yong-Suk Jang; Moon-Sik Yang; Dae-Hyuk Kim
Journal:  Clin Vaccine Immunol       Date:  2011-10-26

5.  Protective vaccination against infectious bursal disease virus with whole recombinant Kluyveromyces lactis yeast expressing the viral VP2 subunit.

Authors:  Marina Arnold; Vijay Durairaj; Egbert Mundt; Katja Schulze; Karin D Breunig; Sven-Erik Behrens
Journal:  PLoS One       Date:  2012-09-14       Impact factor: 3.240

6.  Type IV fimbrial subunit protein ApfA contributes to protection against porcine pleuropneumonia.

Authors:  Lenka Sadilkova; Jiri Nepereny; Vladimir Vrzal; Peter Sebo; Radim Osicka
Journal:  Vet Res       Date:  2012-01-12       Impact factor: 3.683

7.  Attenuated Actinobacillus pleuropneumoniae double-deletion mutant S-8∆clpP/apxIIC confers protection against homologous or heterologous strain challenge.

Authors:  Fang Xie; Gang Li; Long Zhou; Yanhe Zhang; Ning Cui; Siguo Liu; Chunlai Wang
Journal:  BMC Vet Res       Date:  2017-01-06       Impact factor: 2.741

8.  Isolation and characterization of atypical Actinobacillus pleuropneumoniae serovar 15 lacking the apxIICA genes in Japan.

Authors:  Kaho Teshima; Haruna Hirano; Kazutada Ushiyama; Kazumoto Shibuya; Shinya Nagai; Chihiro Sasakawa; Ho To
Journal:  J Vet Med Sci       Date:  2019-02-01       Impact factor: 1.267

9.  Enhancement of protective immune responses by oral vaccination with Saccharomyces cerevisiae expressing recombinant Actinobacillus pleuropneumoniae ApxIA or ApxIIA in mice.

Authors:  Sung Jae Shin; Seung Won Shin; Mi Lan Kang; Deog Yong Lee; Moon-Sik Yang; Yong-Suk Jang; Han Sang Yoo
Journal:  J Vet Sci       Date:  2007-12       Impact factor: 1.672

10.  A recombinant chimera comprising the R1 and R2 repeat regions of M. hyopneumoniae P97 and the N-terminal region of A. pleuropneumoniae ApxIII elicits immune responses.

Authors:  Seung Heon Lee; Seungwoo Lee; Chanhee Chae; Doug-Young Ryu
Journal:  BMC Vet Res       Date:  2014-02-18       Impact factor: 2.741

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.